TELA Bio (TELA) Q2 2026 Earnings Call Transcript
TELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.
How this was made
The 30-second read
Why it matters
The earnings release introduces fresh financial metrics and a strategic shift, providing new data for traders.
Market read
The earnings miss and cash concerns are likely to pressure TELA's stock in the short term, while international growth offers a longer‑term upside narrative.
What to watch
Potential cost‑cutting plan and cash‑runway extension may stabilize balance sheet.
Background
TELA Bio is a medical‑device company focused on hernia repair meshes. The Q2 2026 call disclosed its first earnings after a new CEO appointment.
Ticker impact
Q2 2026 earnings released with revenue decline, net loss widening and cash runway concerns.
Potential further decline in share price until cash‑runway plan is clarified.
Revenue down 4% and net loss expanding, combined with reduced cash, indicate near‑term risk.
Market effects
Heritage surgical mesh market faces pricing pressure from robotic procedures.
International revenue growth may benefit European surgical suppliers.
Limited to niche medical device sector.
Counterpoint
International growth and unit‑volume gains could offset US pricing headwinds over the longer term.
Key entities
- ExecutiveHeather Getz
New CEO commenting on cash‑runway plan.
- ExecutiveJeffrey Blizard
President discussing sales‑force productivity.
